Facial Recognition Can Reduce Racial Profiling and False Arrests

Facial Recognition Can Reduce Racial Profiling and False Arrests

The use of face recognition technology is expanding exponentially right now.

(© Prostock-studio/Adobe)


Keep Reading Keep Reading
Jonathan Turley
Professor Jonathan Turley is a nationally recognized legal scholar who has written extensively in areas ranging from constitutional law to legal theory to tort law. He holds the prestigious Shapiro Chair for Public Interest Law at the George Washington University Law School. In addition to his extensive publications, he has served as counsel in some of the most notable cases in the last two decades including the representation of whistleblowers, military personnel, former cabinet members, judges, members of Congress, and a wide range of other clients. Professor Turley is a frequent witness before Congress on constitutional and statutory issues. He is also a nationally recognized legal commentator and columnist as well as a television commentator. He was ranked as 38th in the top 100 most cited “public intellectuals” (and second most cited law professor) in a study by Judge Richard Posner. Professor Turley received his B.A. at the University of Chicago and his J.D. at Northwestern. In 2008, he was given an honorary Doctorate of Law from John Marshall Law School for his contributions to civil liberties and the public interest.
Get our top stories twice a month
Follow us on
The Friday Five: Soon Band-Aids Could Be AIs

In this week's Friday Five, research on a "smart" bandage for wounds, a breakthrough in fighting inflammation, the pros and cons of a new drug for Alzheimer's, benefits of the Mediterranean diet with a twist, and we've learned to recycle a plastic that was un-recyclable.

Adobe Stock

The Friday Five covers five stories in research that you may have missed this week. There are plenty of controversies and troubling ethical issues in science – and we get into many of them in our online magazine – but this news roundup focuses on scientific creativity and progress to give you a therapeutic dose of inspiration headed into the weekend.

Keep Reading Keep Reading
Matt Fuchs

Matt Fuchs is the editor-in-chief of Leaps.org. He is also a contributing reporter to the Washington Post and has written for the New York Times, Time Magazine, WIRED and the Washington Post Magazine, among other outlets. Follow him on Twitter @fuchswriter.

Sexually Transmitted Infections are on the rise. This drug could stop them.

Cases of gonorrhea, chlamydia and syphilis soared last year, but researchers are finding that a drug known as doxy seems to reduce the number of infections.

Adobe Stock

Sexually transmitted infections (STIs) are surging across the U.S. to 2.5 million cases in 2021 according to preliminary data from the CDC. A new prevention and treatment strategy now in clinical trials may provide a way to get a handle on them.

It's easy to overlook the soaring rates of gonorrhea, chlamydia, and syphilis because most of those infections have few or no symptoms and can be identified only through testing. But left untreated, they can lead to serious damage to nerves and tissue, resulting in infertility, blindness, and dementia. Infants developing in utero are particularly vulnerable.

Keep Reading Keep Reading
Bob Roehr
Bob Roehr is a biomedical journalist based in Washington, DC. Over the last twenty-five years he has written extensively for The BMJ, Scientific American, PNAS, Proto, and myriad other publications. He is primarily interested in HIV, infectious disease, immunology, and how growing knowledge of the microbiome is changing our understanding of health and disease. He is working on a book about the ways the body can at least partially control HIV and how that has influenced (or not) the search for a treatment and cure.